Persistent user bias in case-crossover studies in pharmacoepidemiology

American Journal of Epidemiology

Volumn 184, Issue 10, 2016, Pages 761-769

  Hallas, Jesper ^a   Pottegård, Anton ^b   Wang, Shirley ^a   Schneeweiss, Sebastian ^a   Gagne, Joshua J ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Case crossover design; Drug utilization; Epidemiologic methods; Pharmacoepidemiology; Research design; Self controlled designs

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; THYROXINE;

CONFIDENCE INTERVAL; DESIGN; DISEASE CONTROL; DRUG USER; EPIDEMIOLOGY; PERSISTENCE; POLLUTION EXPOSURE; RISK FACTOR;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CASE CONTROL STUDY; CROSSOVER PROCEDURE; DRUG EXPOSURE; DRUG UTILIZATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERSISTENT USER BIAS; PHARMACOEPIDEMIOLOGY; RETINA DETACHMENT; STUDY DESIGN; SYSTEMATIC ERROR; WRIST FRACTURE; AGING; EPIDEMIOLOGY; EXERCISE; MEMORY; META ANALYSIS; ODDS RATIO; PROCEDURES; STANDARDS; STATISTICAL BIAS; STATISTICAL MODEL; STATISTICS; VERY ELDERLY;

GERMANY;

AGED; AGED, 80 AND OVER; AGING; BIAS; CASE-CONTROL STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); CROSS-OVER STUDIES; EXERCISE; FEMALE; HUMANS; MALE; MEMORY; MODELS, STATISTICAL; ODDS RATIO; PHARMACOEPIDEMIOLOGY; STATISTICS AS TOPIC;

EID: 85014839850     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kww079     Document Type: Article

References (32)

1. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133(2):144-153.
2. Maclure M, Fireman B, Nelson JC, et al. When should case-only designs be used for safety monitoring of medical products. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1): 50-61.
3. Hallas J, Pottegård A. Use of self-controlled designs in pharmacoepidemiology. J Intern Med. 2014;275(6):581-589.
4. Delaney JA, Suissa S. The case-crossover study design in pharmacoepidemiology. Stat Methods Med Res. 2009;18(1): 53-65.
5. Suissa S. The case-time-control design. Epidemiology. 1995; 6(3):248-253.
6. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health. 2011;39(7 suppl): 30-33.
7. Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011; 39(7 suppl):38-41.
8. Pedersen CB. The Danish Civil Registration System. Scand J Public Health. 2011;39(7 suppl):22-25.
9. Thygesen LC, Daasnes C, Thaulow I, et al. Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation, archiving. Scand J Public Health. 2011;39(7 suppl):12-16.
10. Pottegård A, Hallas J. Assigning exposure duration to single prescriptions by use of the waiting time distribution. Pharmacoepidemiol Drug Saf. 2013;22(8):803-809.
11. Muller JE, Mittleman MA, Maclure M, et al. Triggering myocardial infarction by sexual activity. Low absolute risk and prevention by regular physical exertion. Determinants of Myocardial Infarction Onset Study Investigators. JAMA. 1996;275(18):1405-1409.
12. Mittleman MA, Maclure M, Sherwood JB, et al. Triggering of acute myocardial infarction onset by episodes of anger. Determinants of Myocardial Infarction Onset Study Investigators. Circulation. 1995;92(7):1720-1725.
13. Mittleman MA, Maclure M, Tofler GH, et al. Triggering of acute myocardial infarction by heavy physical exertion. Protection against triggering by regular exertion. Determinants of Myocardial Infarction Onset Study Investigators. N Engl J Med. 1993;329(23):1677-1683.
14. Gaist D, Sørensen HT, Hallas J. The Danish prescription registries. Dan Med Bull. 1997;44(4):445-448.
15. Wildenschild C, Mehnert F, Thomsen RW, et al. Registration of acute stroke: validity in the Danish Stroke Registry and the Danish National Registry of Patients. Clin Epidemiol. 2013;6: 27-36.
16. Krarup L-H, Boysen G, Janjua H, et al. Validity of stroke diagnoses in a national register of patients. Neuroepidemiology. 2007;28(3):150-154.
17. Vestergaard P, Mosekilde L. Fracture risk in patients with celiac disease, Crohn's disease, ulcerative colitis: a nationwide follow-up study of 16, 416 patients in Denmark. Am J Epidemiol. 2002;156(1):1-10.
18. Pasternak B, Svanström H, Melbye M, et al. Association between oral fluoroquinolone use and retinal detachment. JAMA. 2013;310(20):2184-2190.
19. Hallas J, Bjerrum L, Støvring H, et al. Use of a prescribed ephedrine/caffeine combination and the risk of serious cardiovascular events: a registry-based case-crossover study. Am J Epidemiol. 2008;168(8):966-973.
20. Danish Medicines Agency. MEDSTAT. DK [database; in Danish]. http://medstat. dk/da/viewDataTables/medicineAndMedicalGroups/%7B%22year%22:%5B% 222012%22,%222011%22,%222010%22,%222009%22,% 222008%22,%222007%22,%222006%22,%222005%22,% 222004%22,%222003%22,%222002%22%5D,%22region% 22:%5B%220%22%5D,%22gender%22:%5B%22A%22% 5D,%22ageGroup%22:%5B%22A%22%5D,% 22searchVariable%22:%5B%22people-count%22%5D,% 22errorMessages%22:%5B%5D,%22atcCode%22:%5B% 22C10AA%22%5D,%22sector%22:%5B%220%22%5D% 7D. Accessed September 21, 2016.
21. Gutierrez J, Ramirez G, Rundek T, et al. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med. 2012;172(12):909-919.
22. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349-1357.
23. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623-1630.
24. Amarenco P, Bogousslavsky J, Callahan A, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-559.
25. Jadhav SB, Jain GK. Statins and osteoporosis: new role for old drugs. J Pharm Pharmacol. 2006;58(1):3-18.
26. Yue J, Zhang X, Dong B, et al. Statins and bone health in postmenopausal women: a systematic review of randomized controlled trials. Menopause. 2010;17(5):1071-1079.
27. Esposito K, Capuano A, Sportiello L, et al. Should we abandon statins in the prevention of bone fractures. Endocrine. 2013;44(2):326-333.
28. Penã JM, Aspberg S, MacFadyen J, et al. Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial. JAMA Intern Med. 2015;175(2):171-177.
29. Greenland S. Confounding and exposure trends in case-crossover and case-time-control designs. Epidemiology. 1996;7(3):231-239.
30. Whitaker HJ, Farrington CP, Spiessens B, et al. Tutorial in biostatistics: the self-controlled case series method. Stat Med. 2006;25(10):1768-1797.
31. Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology. 1996;7(5):478-484.
32. Wang S, Linkletter C, Maclure M, et al. Future cases as present controls to adjust for exposure trend bias in case-only studies. Epidemiology. 2011;22(4):568-574.